COAG logo

COAG Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ Global Market · Biotechnology · Healthcare

$39.29
-0.57 (-1.43%)

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 c…

Market Cap: $1.84Bwww.hemab.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
51
5 mentions
—
60d
51
6 mentions
—
90d
51
6 mentions
—
news: 6

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 0Sell 0Strong Sell 0
Avg price target$54.5+38.7%
Low $36Median $55High $70
Current Consensus

Revenue

$0.00
$0.00
Dec 31Sep 30

Analyst Estimates

FY2025
$-75.36
$-75.36–$-75.36
2 analysts
FY2026
$-3.01
$-3.08–$-2.92
4 analysts
FY2027
$-2.56
$-2.76–$-2.36
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Benny Sorensen
Sector
Healthcare
Industry
Biotechnology
Employees
59
Beta
1.85
Country
US
www.hemab.com